書籍情報から探す
Pathogenesis and Therapeutic Strategies of Alzheimer's Disease
Jae-Hong Lee
Dept. of Neurology, Univ. Ulsan College of Medicine, Asan Medical Center
Neurological Therapeutics 38 (6) S89-S89, 2021.
Dept. of Neurology, Univ. Ulsan College of Medicine, Asan Medical Center
Neurological Therapeutics 38 (6) S89-S89, 2021.
- 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
Neurovascular unit crosstalk with systemic biology : a paradigm for translational stroke research
Eng H. Lo
Massachusetts General Hospital / Harvard Medical School
Neurological Therapeutics 38 (6) S90-S90, 2021.
Massachusetts General Hospital / Harvard Medical School
Neurological Therapeutics 38 (6) S90-S90, 2021.
- 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
Transcriptomic and Gene Therapy Successes in Treating CNS Diseases
C.Anthony Altar
President and Chief Operating Officer of Splice Therapeutics and Co-chairman of the Program Committee of the American Society for Experimental Neurotherapeutics (ASENT))
Neurological Therapeutics 38 (6) S106-S106, 2021.
President and Chief Operating Officer of Splice Therapeutics and Co-chairman of the Program Committee of the American Society for Experimental Neurotherapeutics (ASENT))
Neurological Therapeutics 38 (6) S106-S106, 2021.
- 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
Roles of oligodendrocyte precursor cells in cerebrovascular diseases
Ken Arai
Massachusetts General Hospital / Harvard Medical School
Neurological Therapeutics 38 (6) S116-S116, 2021.
Massachusetts General Hospital / Harvard Medical School
Neurological Therapeutics 38 (6) S116-S116, 2021.
- 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
Donanemabの臨床開発とバイオマーカー : 第II相試験におけるアミロイドプラーク量の変化
佐藤祥一郎1, Sergey Shcherbinin2, Scott W Andersen2, Cynthia Duggan Evans2, Albert Lo2, Ming Lu3, Michael Navitsky3, Emily C Collins2,3, John R Sims2, Dawn A Brooks2, Mark A Mintun2,3
1日本イーライリリー株式会社研究開発・メディカルアフェアーズ統括本部, 2Eli Lilly and Company, 3Avid Radiopharmaceuticals
神経治療学 38 (6) S191-S191, 2021.
1日本イーライリリー株式会社研究開発・メディカルアフェアーズ統括本部, 2Eli Lilly and Company, 3Avid Radiopharmaceuticals
神経治療学 38 (6) S191-S191, 2021.
- 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
AOD1-2. iPS細胞創薬に基づいた筋萎縮性側索硬化症 (ALS) に対するロピニロール塩酸塩の医師主導治験 (ROPALS試験)
森本悟1,2, 高橋愼一1,2,3, 伊東大介2, 伊達悠岳2, 岡田健佑2, Muh Chyi Chai1,4, 西山亜由美5, 鈴木直輝5, 平井美和6, 加部泰明6, 末松誠6, 陣崎雅弘7, 青木正志5, 佐藤泰憲8, 中原仁2, 鈴木則宏2, 岡野栄之1
1慶應義塾大学医学部生理学教室, 2慶應義塾大学医学部神経内科, 3埼玉医科大学国際医療センター脳神経内科・脳卒中内科, 4慶應義塾大学グローバルリサーチインスティテュート, 5東北大学大学院医学系研究科神経内科学, 6慶應義塾大学医学部医化学教室, 7慶應義塾大学医学部放射線科学教室, 8慶應義塾大学医学部衛生学公衆衛生学教室
神経治療学 38 (6) S261-S261, 2021.
1慶應義塾大学医学部生理学教室, 2慶應義塾大学医学部神経内科, 3埼玉医科大学国際医療センター脳神経内科・脳卒中内科, 4慶應義塾大学グローバルリサーチインスティテュート, 5東北大学大学院医学系研究科神経内科学, 6慶應義塾大学医学部医化学教室, 7慶應義塾大学医学部放射線科学教室, 8慶應義塾大学医学部衛生学公衆衛生学教室
神経治療学 38 (6) S261-S261, 2021.
- 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
AOD2-8. CADASIL患者を対象としたアドレノメデュリン静注療法による安全性および有効性に関する多施設共同単群試験
OD2-3. ALS患者への多専門職種チームによる戦略的アプローチ : ALS/MNDセンターの設立と展望
木田耕太1, 林健太郎1,6, 木村英紀1,6, 清水俊夫1,6, 川田明広1,6, 長尾雅裕1,6, 早乙女貴子2,6, 本間武蔵2,6, 大塲優子3,6, 清水尚子3,6, 新井玉南3,6, 村上未来3,6, 塙良江3, 奥山典子4,6, 中山優季5,6, 松田千春5,6, 原口道子5,6, 高橋一司1
1東京都立神経病院脳神経内科, 2東京都立神経病院リハビリテーション科, 3東京都立神経病院看護科, 4東京都立神経病院地域療養支援室, 5東京都医学総合研究所難病ケア看護, 6東京都立神経病院ALS/MNDセンター
神経治療学 38 (6) S267-S267, 2021.
1東京都立神経病院脳神経内科, 2東京都立神経病院リハビリテーション科, 3東京都立神経病院看護科, 4東京都立神経病院地域療養支援室, 5東京都医学総合研究所難病ケア看護, 6東京都立神経病院ALS/MNDセンター
神経治療学 38 (6) S267-S267, 2021.
- 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
OD5-5. 小脳型多系統萎縮症 / 一次進行型多発性硬化症モデルマウスの樹立とこれら疾患の新規創薬ターゲットの探索
OD9-1. Long-term efficacy of satralizumab in patients with NMOSD in the SAkura studies
Manabu Araki1, B Greenberg2, J Bennett3, J de Seze4, I Kleiter5, L Szczechowski6, E Fox7, B Weinshenker8, C von Budingen9, D Stokmaier9, G Klingelschmitt9, K Weber9, C Costantino9, A Traboulsee10, Takashi Yamamura11
1Department of Neurology, Kawakita General Hospital, 2UTSMC, 3UCD, 4HH, 5RUB, 6SCN, 7CTN, 8Mayo, 9Roche, 10UBC, 11Department of Immunology, National Institute of Neuroscience, National Center of Neurology and Psychiatry
Neurological Therapeutics 38 (6) S281-S281, 2021.
1Department of Neurology, Kawakita General Hospital, 2UTSMC, 3UCD, 4HH, 5RUB, 6SCN, 7CTN, 8Mayo, 9Roche, 10UBC, 11Department of Immunology, National Institute of Neuroscience, National Center of Neurology and Psychiatry
Neurological Therapeutics 38 (6) S281-S281, 2021.
- 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
OD10-3. ENVISION試験 : 継続投与24ヶ月時点でのGivosiranの有効性と安全性
Tomohide Adachi1, H Bonkovsky2, P Ventura3, L Gouya4, P Peiro5, D Bissell6, P Stein7, M Balwani8, D Anderson9, C Parker10, D Kuter11, S Monroy12, J Oh13, B Ritchie14, J Ko15, Z Hua15, M Sweetser15, E Sardh16
1Tokyo Saiseikai Central Hospital, 2Wake Forest Baptist Medical Center, 3University of Modena and Reggio Emilia, 4Centre France des Porphyries, 5Hospital Clinic Barcelona, 6University of California, 7King's College Hospital, 8Icahn School of Medicine at Mt. Sinai, 9University of Texas Medical Branch, 10University of Utah, 11Massachusetts General Hospital, 12Instituto Nacional de Pediatria de Mexico, 13Konkuk University Medical Center, 14University of Alberta Hospital, 15Alnylam Pharmaceuticals, 16Karolinska University Hospital
神経治療学 38 (6) S283-S283, 2021.
1Tokyo Saiseikai Central Hospital, 2Wake Forest Baptist Medical Center, 3University of Modena and Reggio Emilia, 4Centre France des Porphyries, 5Hospital Clinic Barcelona, 6University of California, 7King's College Hospital, 8Icahn School of Medicine at Mt. Sinai, 9University of Texas Medical Branch, 10University of Utah, 11Massachusetts General Hospital, 12Instituto Nacional de Pediatria de Mexico, 13Konkuk University Medical Center, 14University of Alberta Hospital, 15Alnylam Pharmaceuticals, 16Karolinska University Hospital
神経治療学 38 (6) S283-S283, 2021.
- 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
OD12-2. Real-world patient-reported impact of MG : initial data from the MyRealWorld MG Study
村井弘之1, Kristl Claeys2, Marguerite Friconneau3, Mark Larkin4, Jing Shao5
1国際医療福祉大学医学部脳神経内科, 2Univ Hospital Leuven, 3AFM-Telethon, 4Vitaccess, 5argenx Japan
Neurological Therapeutics 38 (6) S287-S287, 2021.
1国際医療福祉大学医学部脳神経内科, 2Univ Hospital Leuven, 3AFM-Telethon, 4Vitaccess, 5argenx Japan
Neurological Therapeutics 38 (6) S287-S287, 2021.
- 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
OD15-1. NfL as a Potential Biomarker of Treatment Response in h ATTR Amyloidosis : From Patisiran OLE Study
Yoshiki Sekijima1, Michael Polydefkis2, Simina Ticau3, David Erbe3, Anastasia McManus3, Emre Aldinc3, David Adams4, Mary M Reilly5, Akshay Vaishnaw3, Paul Nioi3
1Shinshu University School of Medicine, 2Johns Hopkins University School of Medicine, 3Alnylam Pharmaceuticals, 4APHP, CHU Bicetre, Universite Paris-Saclay, 5MRC Centre for Neuromuscular Diseases, UCL Queen Square Institute of Neurology
Neurological Therapeutics 38 (6) S293-S293, 2021.
1Shinshu University School of Medicine, 2Johns Hopkins University School of Medicine, 3Alnylam Pharmaceuticals, 4APHP, CHU Bicetre, Universite Paris-Saclay, 5MRC Centre for Neuromuscular Diseases, UCL Queen Square Institute of Neurology
Neurological Therapeutics 38 (6) S293-S293, 2021.
- 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
OD15-2. HELIOS-A : Phase 3 Study of Vutrisiran in Patients with ATTRv Amyloidosis with Polyneuropathy
Mitsuharu Ueda1, David Adams2, Ivailo L Tournev3,4, Mark S Taylor5, Teresa Coelho6, Violaine Plante-Bordeneuve7, John L Berk8, Alejandra Gonzalez-Duarte9, Julian D Gillmore10, Soon-Chai Low11, Yoshiki Sekijima12, Laura Obici13, Rick Blakesley14, Seth Arum14, Rebecca Shilling14, John Vest14, Michael Polydefkis15
1Kumamoto University, 2Universite Paris-Saclay, 3Medical University - Sofia, 4New Bulgarian University, 5University of Sydney, 6Hospital de Santo Antonio, 7Assistance Publique Hopitaux de Paris, 8Boston Medical Center, 9Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, 10National Amyloidosis Centre, 11University of Malaya, 12Shinshu University School of Medicine, 13Amyloidosis Research and Treatment Centre, 14Alnylam Pharmaceuticals, 15Johns Hopkins University School of Medicine
Neurological Therapeutics 38 (6) S293-S293, 2021.
1Kumamoto University, 2Universite Paris-Saclay, 3Medical University - Sofia, 4New Bulgarian University, 5University of Sydney, 6Hospital de Santo Antonio, 7Assistance Publique Hopitaux de Paris, 8Boston Medical Center, 9Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, 10National Amyloidosis Centre, 11University of Malaya, 12Shinshu University School of Medicine, 13Amyloidosis Research and Treatment Centre, 14Alnylam Pharmaceuticals, 15Johns Hopkins University School of Medicine
Neurological Therapeutics 38 (6) S293-S293, 2021.
- 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
PD4-4. Swallowing function in infants who started nusinersen in pre-symptomatic SMA : from the NURTURE study
T Wataya1, VA. Sansone2, KJ. Swoboda3, DC. De Vivo4, E Bertini5, WL Hwu6, C Makepeace1, J Bohn1, R Chin1, S Raynaud1, A Paradis1
1Biogen, 2University of Milan, 3Massachusetts General Hospital, 4Columbia University Irving Medical Center, 5Post-Graduate Bambino Gesu Children's Researc Hospital, 6National Taiwan University Hospital
Neurological Therapeutics 38 (6) S313-S313, 2021.
1Biogen, 2University of Milan, 3Massachusetts General Hospital, 4Columbia University Irving Medical Center, 5Post-Graduate Bambino Gesu Children's Researc Hospital, 6National Taiwan University Hospital
Neurological Therapeutics 38 (6) S313-S313, 2021.
- 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
PD4-5. Japan REgistry for Adult subjeCTs of spinal muscular atrophy (jREACT) : A study protocol
Kentaro Sahashi1, Atsushi Hashizume1, Yachiyo Kuwatsuka2, Madoka Chinen3, Ai Saotome3, Masahiko Ando2, Masahisa Katsuno1
1Department of Neurology, Nagoya University Graduate School of Medicine, 2Department of Advanced Medicine, Nagoya University Hospital, 3Biogen Japan
Neurological Therapeutics 38 (6) S314-S314, 2021.
1Department of Neurology, Nagoya University Graduate School of Medicine, 2Department of Advanced Medicine, Nagoya University Hospital, 3Biogen Japan
Neurological Therapeutics 38 (6) S314-S314, 2021.
- 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。
PD4-6. Nusinersen in SMA children who received onasemnogene abeparvovec : a phase 4, RESPOND study design
T Wataya1, JA. Parsons2, JF. Brandsema3, RS. Finkel4, C Proud5, KJ. Swoboda6, Richard Foster1, C Makepeace1, A Paradis1, R Chin1, Z Berger1, W Farwell1
1Biogen, 2Children's Hospital Colorado, 3Children's Hospital of Philadelphia, 4St. Jude Children's Research Hospital, 5Children's Hospital of The King's Daughters, 6Massachusetts General Hospital
Neurological Therapeutics 38 (6) S314-S314, 2021.
1Biogen, 2Children's Hospital Colorado, 3Children's Hospital of Philadelphia, 4St. Jude Children's Research Hospital, 5Children's Hospital of The King's Daughters, 6Massachusetts General Hospital
Neurological Therapeutics 38 (6) S314-S314, 2021.
- 全文ダウンロード: 従量制、基本料金制の方共に121円(税込) です。